ATLANTA, GA – – (Globe Newswire – August 28, 2024) – – A shareholder class action lawsuit has been filed against Verve Therapeutics, Inc. (“Verve Therapeutics” or “the Company”) (NASDAQ: VERV). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts about the Company’s business, operations, and prospects, including allegations that: (1) Defendants did not fully disclose the circumstances under which the Heart-1 trial would be halted; and (2) Defendants overstated the potential benefits of its proprietary LNP delivery system.

If you bought shares of Verve Therapeutics between August 9, 2022 and April 1, 2024, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/verve-therapeutics/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is October 28, 2024.